Bristol-Myers Squibb Company Ce
CELG-RI · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $10 | $11 | $9 | $14 |
| + Debt | $51 | $41 | $41 | $46 |
| Enterprise Value | $41 | $30 | $32 | $32 |
| Revenue | $48 | $45 | $46 | $46 |
| % Growth | 7.3% | -2.5% | -0.5% | – |
| Gross Profit | $27 | $34 | $36 | $36 |
| % Margin | 56.8% | 76.2% | 78% | 78.6% |
| EBITDA | $3 | $19 | $19 | $20 |
| % Margin | 6.6% | 43% | 41.6% | 43.4% |
| Net Income | -$9 | $8 | $6 | $7 |
| % Margin | -18.5% | 17.8% | 13.7% | 15.1% |
| EPS Diluted | -4.41 | 3.86 | 2.95 | 3.12 |
| % Growth | -214.2% | 30.8% | -5.4% | – |
| Operating Cash Flow | $15 | $14 | $13 | $16 |
| Capital Expenditures | -$1 | -$1 | -$1 | -$1 |
| Free Cash Flow | $14 | $13 | $12 | $15 |